A chemotherapy regimen was able to treat a woman’s neuromyelitis optica spectrum disorder (NMOSD) which was likely secondary to follicular lymphoma, a type of cancer that begins in cells of the immune system, according to a case report by researchers at King’s College London in the U.K. O-CVP —…
treatment
Among people with neuromyelitis optica spectrum disorder (NMOSD) who started treatment with Uplizna (inebilizumab-cdon) in a clinical trial, an early and strong reduction in B-cell counts was associated with a quicker decline in disease activity. This report comes from an analysis of data from the Phase 2/3…
A young woman had a rebound of neuromyelitis optica spectrum disorder (NMOSD) toward the end of her pregnancy, for which she underwent plasma exchange and took steroids, according to a report from researchers in the U.S. Because treatment with plasma exchange and steroids did not work well enough, the…
Treatment with Uplizna (inebilizumab-cdon) can reduce levels of antibodies that drive neuromyelitis optica spectrum disorder (NMOSD), new clinical trial data show. The data also show that, among patients who aren’t on Uplizna, NMOSD attacks are often preceded by a sharp rise in levels of disease-driving antibodies and/or antibody-producing…
Rituximab may be effective for improving functionality in children with neuromyelitis optica spectrum disorder (NMOSD) or other inflammatory neurological disorders, though more research is needed to identify optimal treatment regimens, a new study reports. “Efficacy of [rituximab] in specific indications and good tolerance are confirmed in pediatric neurology.
The approved therapy Edaravone, used for amyotrophic lateral sclerosis (ALS) and stroke, may be a promising treatment for neuromyelitis optica spectrum disorder (NMOSD), according to a new study. The use of edaravone in NMOSD cell and mouse models promoted restoration of the myelin sheath — damaged in immune attacks…
A low dose of rituximab — infused at 100 mg weekly for three consecutive weeks — was effective at preventing relapses and disability progression in people with neuromyelitis optica spectrum disorder (NMOSD), according to a meta-analysis of five different regimens. Moreover, treatment with rituximab at this low…
Reaching a neuromyelitis optica spectrum disorder (NMOSD) diagnosis in the absence of disease-causing antibodies requires careful attention from physicians in order to ensure timely treatment. That suggestion comes from a case report of a man in Nepal who had symptoms of the autoimmune disease but lacked the antibodies against…
Women with neuromyelitis optica spectrum disorder (NMOSD) who received immunosuppressive treatment during pregnancy or were at least 32 years old when they conceived may be at a lower risk of pregnancy-associated relapses, a systematic review study has found. Data also showed the risk of relapse is highest in the…
SinoMab BioScience has been cleared by Chinese regulators to launch a clinical trial for its experimental immune-suppressing therapy SN1011 in people with neuromyelitis optica spectrum disorder (NMOSD). The company is anticipating that the Phase 2/3 trial will begin enrolling participants in early 2023. “The IND [investigational new drug]…
Recent Posts
- New antibody may explain mystery cases of NMOSD-like disease
- Are those mystery aches and pains due to NMOSD or regular life?
- NMOSD therapy linked to fewer attacks, less disability in Chinese study
- Where I go to recharge from the daily challenges of NMOSD
- Clinical trial data show NMOSD treatment reduces relapses